2017
Oils4cure constituted.
2017
Application for registration of a clinical trial project with the AEMPS.
2017
Plant Variety Registration (YCJ-01 / YCJ-02).
2018
Start of the R&D process for the development of investigational medicinal products.
2020
Completion of the development of the first drug YCJ-01 for Refractory Epilepsy.
2021
Application for a Phase II clinical trial for refractory epilepsy in Tuberous Sclerosis.
2022
Phase III clinical trial application for refractory epilepsy in Tuberous Sclerosis.
2023
Approval of Phase III clinical trial for refractory epilepsy in Tuberous Sclerosis.
June 2024
Start of Phase III clinical trial for refractory epilepsy in Tuberous Sclerosis.
October 2026
Completion of Phase III clinical trial for refractory epilepsy in Tuberous Sclerosis.
January 2027
Registration of the medicinal product YCJ-01.
June 2027
Distribution and marketing.
In progress
Completion of development of the second drug YCJ-02 for spasticity and neuropathic pain.